



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



dCBP-1

Cat. No.:	HY-134582
CAS No.:	2484739-25-3
Molecular Formula:	C ₅₁ H ₆₃ F ₂ N ₁₁ O ₁₀
Molecular Weight:	1028.11
Target:	Epigenetic Reader Domain; PROTACs
Pathway:	Epigenetics; PROTAC
Storage:	-20°C, sealed storage, away from moisture and light * In solvent : -80°C, 1 years; -20°C, 6 months (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (48.63 mM; ultrasonic and warming and heat to 80°C)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM	0.9727 mL	4.8633 mL	9.7266 mL	
		5 mM	0.1945 mL	0.9727 mL	1.9453 mL	
		10 mM	0.0973 mL	0.4863 mL	0.9727 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 5 mg/mL (4.86 mM); Clear solution; Need ultrasonic					
	2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (2.43 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP based on Cereblon ligand. dCBP-1 is exceptionally potent at killing multiple myeloma cells and ablates oncogenic enhancer activity driving MYC expression ^[1] .	
IC ₅₀ & Target	p300/CBP	Cereblon
In Vitro	dCBP-1 (10-1000 nM; 6 hours) treatment shows near-complete degradation of p300/CBP in MM1S cells. dCBP-1 is also able to induce near-complete p300/CBP degradation across other multiple myeloma cell lines tested, including MM1R, KMS-12-BM, and KMS34 ^[1] . ?Treatment of the human haploid cell line HAP1 for 6 h with dCBP-1 reveals almost complete loss of both CBP and p300 between 10 and 1000 nM doses. A time course analysis with 250 nM dCBP-1 revealed almost complete degradation of p300/CBP within an hour of treatment ^[1] .	

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	Multiple myeloma cell line MM1S
Concentration:	10 nM, 100 nM, 250 nM, 500 nM, 1000 nM
Incubation Time:	6 hours
Result:	Revealed rapid degradation with near-complete loss of p300/CBP after 2 hours.

REFERENCES

[1]. Raghu Vannam, et al. Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. Cell Chem Biol. 2020 Dec 31;S2451-9456(20)30513-4.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA